Atlas Trials

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Clinical trial NCT03786783 · COMPLETED

Trial details

NCT number
NCT03786783
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
GanglioneuroblastomaHigh Risk Neuroblastoma
Start date
2019-03-04
Primary completion
2021-12-31
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.